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Abstract
This study investigated the efficacy of Home-Based Renal Care (HBRC) in diabetic Zuni
Indians with Chronic Kidney Disease (CKD) in New Mexico using propensity scores. Home
based intervention as opposed to standard clinical care is a pragmatic treatment approach that
incorporates the preference of population in hopes of addressing a cultural barrier to healthcare
in this high risk population. This study uses a logistic regression model and a linear regression
model to estimate the average effect of HBRC on increasing the likelihood of participants taking
a more active role in the management of their chronic condition compared to the control group.
We used generalized estimating equations (GEE) to account for household clustering and
stabilized inverse probability of treatment weighting (SIPTW) to reduce any estimate bias that
may have been introduced.
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Chapter 1
Introduction
In 2013, Americans spent an estimated 101.4 billion US dollars on diabetes mellitus management
making it the largest spending on a health condition in the United States.1 Though alarming, it does not
come as a surprise that the prevalence of diabetes has been on the rise in the last couple of decades. The
estimated percentage of Americans diagnosed with diabetes has doubled from 4% to 8.4% between 1999
and 2018.2 Diabetes impacts the quality of life of many Americans.
Furthermore, diabetes is a risk factor for many chronic health conditions. For example, diabetes
has been previously described as the leading cause of advanced kidney disease worldwide.3 Specifically,
chronic kidney disease (CKD) affects 13% of the general adult American population diagnosed with type
2 diabetes mellitus (T2DM).4 In high-risk populations, the high prevalence rate of diabetes leads to a
faster progression of CKD. Particularly, studies have demonstrated that CKD is prevalent among ethnic
and racial minorities.5 It is important to recognize that diabetes has been identified as a modifiable risk
factor for CKD progression that disproportionately affect socially disadvantaged groups.
The burden of CKD is greater in ethnic and racial minorities, and rural communities where access
to healthcare is limited.6 For example, the majority of Zuni Indians in New Mexico live in remote parts of
the state and subsequently have limited access to health care. The combination of their lack of access to
health services and high rates of chronic diseases among them masks the true nature of their sickness as
seen with the cardiovascular disease in the Zuni tribe.7 This health disparity is worsened by the barriers of
healthcare. The focus of our work will be on Zuni Indians in New Mexico.
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Cultural barriers are another dimension that goes beyond limited access to health care. However,
many interventions fail to address such barriers specifically by not accounting for the cultural awareness
and the preference of the population of interest. The Zuni Indians, for instance, have experienced
considerable historical and cultural trauma that resulted in fear of participating in health screening and
healthcare.8 In addition to the fear, the mistrust and difficulty in building a trusting relationship with
healthcare providers, due to the high turnover rate of medical staff at the Indian Health Services, were
identified as barriers within the operation of health care systems.7
Home based intervention as opposed to standard clinical care addresses another barrier to
healthcare—the preference of population. For instance, a recent study found that the Zuni Indians in New
Mexico culturally preferred to receive care where confidentiality is easily attained.7 In this community,
going to a clinic, where patients could be seen by others in waiting rooms, could sometimes lead to
feeling embarrassed which in turns might prevent the patients from receiving care at the health services
on a regular basis.
In this study, the proposed intervention was designed to address these barriers by using
community health workers (CHW) who are members of the Zuni tribe but were trained specifically for
the delivery of the intervention. In contrast to standard clinical care, where patients visit clinics, CHWs in
this intervention provided care at patients’ homes which takes into consideration that most patients feel
more comfortable when receiving care from people who look like them. In this 12-month randomized
controlled trial, the intervention was specifically designed to improve patients’ inclination to take a more
active role in the management of their chronic health condition. Hence, the primary outcome of interest of
this study was patient’s activation score which is a measure of their involvement in the health care
management. The objective of this trial is to examine the effectiveness of home-based renal care in
comparison to standard care with respect to patients’ activation scores. We hypothesized that patients
were more likely to engage in their health care management if they received care at home.
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Chapter 2
Methods
The aim of this thesis was to analyze the effectiveness of home-based renal care (HBRC) on
increasing the likelihood of the diabetic Zuni Indians to be more active in the management of CKD. The
primary outcomes of interest were (1) whether patient activation improved where activation is considered
level 3 or greater (binary) and (2) the change in the patient activation score collected through a selfreported questionnaire (continuous). A logistic regression model was used to estimate the odds of
improvement in patient activation level for the intervention group relative to the control group. A linear
regression model was used to estimate the mean patient activation score for patients in the intervention
group relative to controls. Because we enrolled family units into the study, Generalized Estimated
Equations (GEE) were used to account for household clustering.
Participants
Potential participants (n = 1,436) from a previously established cohort were screened for relevant
clinical factors.9 Exactly 315 individuals were screened for eligibility where 127 met the criteria for
inclusion in the study. The criteria included being between 21 and 80 years of age and having urine
albumin : creatinine ratio ≥ 30 kg/m2, hemoglobin A1c ≥ 7%, or a family history of diabetes and kidney
disease. Two individuals declined to participate in the study. The remaining 125 were enrolled in the 12
month randomized controlled trial. The data from 72 individuals who were on diabetes medication (DM)
at baseline were used for the purpose of this thesis.
Randomization
The randomization sequence was generated using the PROC PLAN procedure in SAS to assign
participants to either the standard clinical care group or the home-based renal care group. The
3

randomization procedure permuted the two levels of treatment randomly and without replacement within
blocks containing two, four, or six households. More than one person in a household could participate in
the study. Because of this, we randomized households in a 1:1 allocation to the standard clinical care or
the intervention to ensure that members of the same household were allocated to the same treatment
group. While 96 households were enrolled in the study, only 40 households were enrolled in the diabetic
subset that were analyzed for this thesis; 14 participants enrolled in the standard clinical care and 17
participants enrolled in the intervention group were from single-participant households. Neither the
investigator nor the participants were blinded at randomization because it was clear which participants
were receiving the intervention at home or the standard care at a local Indian Health Service clinic.
Data Flowchart
The data flow from enrollment to randomization to final assignment into the intervention and
control groups is shown in Figure 2.1.

Figure 2.1 Data Flowchart
4

Explanatory Variables
Intervention/Treatment
The intervention group received Home-Based Renal Care (HBRC). The Community Health
Workers (CHWs) were Zuni Indians who were trained to provide the HBRC to the intervention group.
The CHWs received 40 hours of training that consisted of education about CKD and its self-management
education, the theoretical framework of the intervention and its implementation. They visited the
participants on a biweekly basis to educate them on various topics including but not limited to healthy
eating, exercise, medication management and risk factor management.
The intervention focused on providing a pragmatic treatment plan that addressed cultural
awareness. The participants chose to receive care in their native language if preferred by the participant.
The diet and exercise plan incorporated traditional food items and culturally popular activities, and
promoted group cohesion. Receiving care at home reflected the preference of the population that aimed to
reduce any anxiety and discomfort that commonly result from going to the clinic.7 They provided point-of
care testing. This meant that the lab results were taken and interpreted to the participants immediately
during the home visit. They were also provided with cellphones and text message plans, and received
motivational text messages a few times per day.
The control group received standard clinical care from a local Indian Health Services clinic. They
received publicly-available up-to-date information about diabetes prevention, weight loss, diet and
exercise. They were only contacted by the study staff for the purpose of data collection.
Response Variables
Primary Outcomes of Interest
Patient Activation Score
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The patient activation score (PAM score) has been previously reported as a validated tool that
assesses a patient’s ability to effectively participate in his or her care.10 This instrument was collected
through a short form questionnaire consisting 13 questions with 4 response options: (1) strongly disagree,
(2) disagree, (3) agree, and (4) strongly agree. The raw score ranged from 39 to 53. If there were any
missing response, the total score was divided by the number of answered questions and multiplied by 13
to yield a normalized raw score. A nomogram, provided under a licensing agreement with Insignia
Health, converted raw scores to an activation score that ranged from 0 to 100. We note that in this work
we will be using the converted activation score and not the raw score.
Patient Activation Level
The patient activation score was further categorized into 4 levels. They were:
Level 1: Believing the patient’s role is important but not taking action;
Level 2: Having the confidence and knowledge necessary to take action;
Level 3: Taking action to maintain and improve one’s health; and
Level 4: Staying the course even under stress.
Scoring level 3 and higher was grouped into one category representing patient activation. Scoring level 2
and lower was grouped into the other category representing the lack of patient activation. Figure 2.2
shows the identification of each patient activation levels from calibrating the patient activation score from
the 13 item questionnaire.11 The raw score of patient activation scores ranged from 38.6 to 53. A raw
score of 39 to 41, 42 to 47, 50 to 51 and 52 to 53 were calibrated into level 1, level 2, level 3 and level 4
respectively.
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Figure 2.2 Calibration of the patient activation score into patient activation levels
Secondary Outcomes of Interest
Body Mass Index
Among clinicians, Body Mass Index (BMI) has been accepted as the better estimate of total body
fat compared to body weight alone.12 Obesity has been reported to be associated with multiple conditions
that are known to cause compromised renal function such as hypertension and diabetes.13 Also, it was
found that it may be independently associated with the risk of developing CKD.14 Hence, it was measured
to evaluate the degree of excess weight and as a risk factor for CKD in this study. BMI was calculated by
dividing body weight (kg) by height squared (m2).
Blood Pressure
Hypertension is present in estimated 80-85% of patients with CKD.14 The increased prevalence of
hypertension has been primarily caused by sodium retention among other factors and been identified as a
contributory factor in the development of kidney disease.15 For this study, blood pressure (systolic and
diastolic) was measured 3 times about 5 minutes apart with the participants resting in a seated position,
then averaged.
7

Hemoglobin A1c
It has been found that hemoglobin A1c (HbA1c) level in blood reflects the mean blood glucose
over 120-day lifespan of the red blood cell.16 Hence, it is the most widely used clinical test to estimate the
long-term mean blood glucose.16 It is recommended that the target A1c value should be 7% or lower for
most diabetic patients.17 Hemoglobin A1c level (≥ 6.5 %) is a diagnostic criterion for diabetes.18
Serum Glucose
Fasting plasma glucose (≥ 126 mg/dL) is another diagnostic criterion for diabetes.18 It is
important to note that plasma glucose concentration fluctuates within the same day depending on food
intake and other factors. A measure of plasma glucose should be supplemented by a measure of the
hemoglobin A1c.
Serum Total Protein
Adaptive hyperfiltration induces proteinuria and progressive renal failure.19 Hyperfiltration and
proteinuria could lead to changes in the total protein concentration in plasma. Protein malnutrition is a
common finding in chronic renal failure and is associated with poor outcome.20
Serum Cholesterol
Hyperlipidemia refers to high levels of lipids in blood including cholesterol and triglycerides.
This does not directly cause symptoms but has been identified as a risk factor for cardiovascular disease,
diabetes mellitus, and chronic kidney disease.21 Cholesterol is essential for normal function of all animal
cells and is a precursor of various critical substances such as steroid hormones and bile acids.22 A total
cholesterol level of less than 200mg/dL is considered normal.23 A total cholesterol level greater than or
equal to 240 mg/dL is considered high.23
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Serum Triglycerides
Triglycerides is one type of lipid in blood. Triglycerides is different than cholesterol in that
triglycerides represents the main lipid component of dietary fat.22 High triglyceride level is associated
with high risk of cardiovascular disease, diabetes and chronic kidney disease.21 Less than 150 mg/dL is
considered to be normal level and greater than 886 mg/dL is considered very high level of triglycerides.23
Serum HDL Cholesterol
High-density lipoproteins (HDL) is commonly known as the “good” cholesterol because it plays
the role of reverse transporting cholesterol from different tissues to liver where cholesterol is eventually
removed from the body.22 Hence, HDL prevents excess cholesterol build up in the body.22 Greater than or
equal to 60 mg/dL is considered to be normal level whereas less than 40 mg/dL is considered to be lower
than desirable.23
Serum LDL Cholesterol
Low-density lipoproteins (LDL) is rich in cholesterol. LDL delivers cholesterol to cells where it
can be used for normal cell functions.22 High levels of LDL is associated with reduced synthesis of LDL
receptors which then can lead to excess cholesterol accumulation in blood.22 LDL cholesterol in blood is
calculated by subtracting the HDL cholesterol level and the VLDL cholesterol level from the total
cholesterol level.23 For a high risk individual, the recommended LDL level is less than 130 mg/dL.23
Estimated GFR
Serum and urine creatinine were measured by an enzymatic method and estimated glomerular
filtration rate (eGFR) was computed using the Chronic Kidney Disease Epidemiology Collaborations
(CKD-EPI) equation.24 GFR is generally used as the best index of overall kidney function.25 Decline in
GFR is a hallmark of progressive kidney disease.25 Less than 60 mL/min per 1.73 m2 is considered as
decreased GFR.26 Less than 15 mL/min per 1.73 m2 is defined as kidney failure.26
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Urine ACR
Urine albumin-to-creatinine ratio (UACR) is used to estimate 24-hour proteinuria.27 Proteinuria
describes protein excretion in urine. Less than 150 mg/day is considered as normal level of total urinary
protein excretion.28 As UACR is a ratio of albumin to creatinine, it is measured in mg of protein per g of
creatinine.27 Greater than 30 mg/g is considered as an abnormally elevated ACR.28 Individuals with
UACR above this threshold is considered to be at high risk for chronic kidney disease.28
High Sensitivity CRP
High Sensitivity C-reactive protein (hsCRP) is an acute phase protein that is produced by
hepatocytes and is a biomarker of inflammation.29 Its pathogenic role in a specific cause for inflammation
in the development of chronic kidney disease is currently unknown.30 There is no standardized hsCRP
value that is associated with abnormalities.31 However, a study reported elevated hsCRP levels (>8
mg/dL) in 46 percent of its cohort (n=280) who were on chronic hemodialysis.32 We note to take caution
in interpreting the results regarding hsCRP given the lack of clinical understanding of its pathogenic role
in chronic kidney disease.
Morisky Score
The Morisky score was assessed as a measure of adherence with prescribed medicines.33 Higher
score on the scale correspond to improved quality of life.
KDQDL Measures
Health related quality of life was assessed by the Kidney Disease Quality of Life survey
(KDQOL-36).34 Higher scores on the scales corresponded to improved quality of life.
Optimal Cutoffs for Continuous Measures
There were variables that displayed a ceiling effect where the response variable clustered toward
the upper limit of the measurement. There were three such variables—Symptoms/Problems List, Effect of
10

Kidney Disease, and Burden of Kidney Disease. To dichotomize these variables, we first regressed the
Treatment group against each variable via logistic regression modeling and secondly we used the area
under the ROC curve (AUC) to identify the Euclidean distance that maximizes the difference between the
ROC curve and the point (0, 1).35 In turn, this allowed for minimizing the false positive rate while
maximizing the true positive rate. We then applied this optimal cut-off threshold to categorize the three
continuous variables into binary variables—1 indicating improvement of health-related quality of life and
0 indicating lack of improvement of health-related quality of life.
Models
Linear regression
Most of the dependent variables (DVs) that we were interested in were continuous with normal
distribution. For example, the primary outcome of interest in this study was patient activation score which
is a continuous variable. A linear regression model, using the SAS procedure PROC GENMOD, was used
to estimate the treatment effect for the primary exposure on these DVs. In order to account for the
household clustering, using Generalized Estimated Equations in PROC GENMOD rather than PROC
REG was more appropriate.
Logistic regression
There were four variables of interest that were categorized into binary outcomes. For example,
the primary outcome of interest, the patient activation level, was categorized into “activation” vs. “lack of
activation”. A logistic regression model, using the SAS procedure PROC GENMOD, was used to
estimate the treatment effect for the primary exposure on these binary DVs. In order to account for the
household clustering, using Generalized Estimated Equations in PROC GENMOD rather than PROC
REG was more appropriate.
A cross-validation technique was used to examine the generalizability of our findings. We
estimated cross-validation error using a Monte-Carlo approach. A training set (80% of the entire dataset)
11

was randomly selected from the dataset to construct the model. The remaining observations were
collectively named the testing set (20% of the entire dataset). The fitted model was tested using the testing
set. The matric used to evaluate the results from cross-validation were Root Mean Square Error (RMSE),
the mean absolute error (MAE), and R2 in the test set for the continuous DVs and Mean Percentage of
Correct Classifications (MPCC) and its corresponding Standard Error (SE) for binary DVs.
Propensity Score
Propensity score is the probability of receiving treatment given a set of observed covariates.
Traditionally, the propensity score was intended to be used specifically as a method of treatment selection
bias reduction in non-randomized studies. In this thesis, the purpose of using the propensity score was to
adjust for the imbalanced covariates at baseline to obtain more precise estimate for the treatment effect. A
logistic regression model, for which the primary exposure was used as the primary outcome, was utilized
to estimate the propensity scores. The estimated propensity scores were then used to generate Inverse
Probability of Treatment Weights (IPTWs) that eventually were used to account for any imbalance in the
covariates between groups at baseline.
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Chapter 3
Analysis
The primary outcome in this study was patient activation score (PAM score) which was a
continuous measure that ranges from 0 to 100. This was further dichotomized such that patients could be
either in an activation level or in a lack of activation level (PAM level). Two models were fitted to
analyze the data from the 12-month randomized controlled trial: (a) a logistic regression model was used
to analyze the binary response variable “activation/lack of activation” in determining whether patients
have higher odds of being activated in the management of their care, and (b) a linear regression model
was used to analyze patient activation score that ranged from 0 to 100.
Data Visualization
Before any modeling, we visualized the collected data. We generated bar charts to visualize the
changes in the patient activation levels from baseline to the 12-month measurements between groups. The
bar charts in Figure 3.1 gave the frequency of participants in each patient activation levels in the control
group and in the intervention group. The bar chart on the left gave the baseline measures and the one on
the right gave the 12-month measures. The yellow bars represented control group and the blue bar
represented intervention group.
At baseline, about 22% of the participants in the control group were in the “lack of activation”
level and about 29% of the participants in the intervention group were in the “lack of activation” level. In
other words, about 78% of the participants in the control group and about 71% of the participants in the
intervention group were in the “activation” level at baseline. At the end of the 12-month randomized
controlled trial (RCT), about 59% of the participants in the control group and about 92% of the
participants in the intervention group were in the “activation” level.
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Figure 3.1 Percent of participants (control and intervention groups) in each PAM levels at baseline and
12 months
We generated histograms of the patient activation score (PAM score) differences between
baseline measurement and the 12 month measurements showing the measured differences between the
control group and the intervention group (Figure 3.2). The yellow represented the control group and the
blue represented the intervention group. The positive differences were dominated by the blue whereas the
negative differences were dominated by the yellow indicating higher improvement in the participants in
the intervention group based on the PAM scores.

Figure 3.2 PAM score differences between groups.
14

Figure 3.3 Change in PAM score between groups
A scatterplot of the PAM score at 12 months against the PAM score at baseline was generated to
visualize the relationship between the baseline and the 12-month patient activation score between groups
(Figure 3.3). The yellow filled dots represented the control group. The blue filled dots represented the
intervention group. The diagonal line represented no change between the PAM scores from baseline to 12
months. If the PAM score increased, then it would be plotted above the line whereas if the PAM score
decreased, then it would be plotted below the line. Mostly, the blue dots representing the intervention
group were plotted above the line whereas the yellow dots representing the control group clustered around
the reference line of no change. There might be a couple of outliers in the data; see further
characterization of the outliers and influential points in chapter 3.
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Baseline Comparison
To make a meaningful interpretation of the treatment effect, it is important to ascertain the
participants in each group had similar baseline characteristics. The sample mean for numerical
demographical variables, primary and secondary outcome measurements was reported as a measure of the
central tendency along with the standard deviation as a measure of variability. As an informal test, we
generated histograms to visualize the distribution of all of the variables by Treatment group. Some of the
variables such as glucose, hemoglobin A1c, cholesterol, triglycerides, urine ACR, high sensitive CRP, the
KDQDL measures displayed skewedness suggesting that the sample data may not be normally
distributed.
Formally, we used the χ2-tests to examine the association between any of the categorical variables
with the Treatment groups. Further, to compare population means between the Treatment groups, we
conducted two samples independent T-tests for continuous variables. To examine the assumptions of the
latter test, we used the Folded F-test to determine the constant variance. If constant variance was
established, then we reported the p-values from the pooled method. If constant variance was violated, then
we reported the p-values from the Satterthwaite approximation method as it does not assume that
variances of the two samples are equal. (Table 3.1)
Because of the skewedness of some of the variables in the data, we also reported the sample
median and the interquartile range for the continuous variables (Table 3.2). We have conducted Wilcoxon
Rank-Signed Tests (WRST) for median comparisons between the Treatment groups. The p-values from
the WRST tests were reported. The sample median and the interquartile range are less sensitive to
extreme observations compared to the sample mean and the standard deviation and hence Table 3.2 might
provide better estimates for central tendency and variability of the data compared to Table 3.1. All
comparisons were made based on the 5% significance level.
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Characteristic

Usual Care,
n=32
Mean (±SD)
or n (%a)

Home-Based Renal Care,
n=24
Mean (±SD)
or n (%)

p-valueb

Demographics
Age, yr
50.9 (±13.0)
47.4 (±11.2)
0.2871
Women
16 (50%)
16 (66.7%)
0.2785
High school education
22 (68.8%)
17 (70.8%)
1.0000
Primary outcome measures
Patient activation total score
63.0 (±11.2)
57.3 (±19.1)
0.1999c
Patient activation level ≥ 3
25 (78.1%)
17 (70.8%)
0.5507
Secondary outcome measures
Body mass index, kg/m2
31.4 (±7.0)
32.8 (±7.8)
0.4877
BP, mm HG
Systolic
126.6 (±15.5)
128 (±12.2)
0.6556
Diastolic
81.8 (±10.5)
80.3 (±12.9)
0.6465
HbA1c, %
8.5 (±2.3)
9.1 (±2.6)
0.3697
Glucose, mg/dl
167.3 (±81.2)
182.9 (±92.4)
0.5035
Serum total protein, mg/dl
7.5 (±0.5)
7.6 (±0.5)
0.6275
Serum cholesterol, mg/dl
175.3 (±35.7)
220.9 (±69.9)
0.0064c
Serum triglycerides, mg/dl
180.9 (±92.6)
411.1 (±656.3)
0.1011c
Serum HDL cholesterol, mg/dl
45.8 (±1.4)
46.6 (±1.5)
0.6505c
Serum LDL cholesterol, mg/dl
105.0 (±30.5)
125.0 (±42.5)
0.0444
2
eGFR, ml/min per 1.73 m
115.1 (±63.7)
148.9 (±63.2)
0.0540
Urine ACR, mg/g
1082.0 (±1631.6)
598.3 (±1372.1)
0.2458
hsCRP, mg/L
0.0191c
3.6 (±3.6)
10.7 (±13.2)
Morisky scored
3.9 (±2.2)
4.3 (±1.8)
0.4109
KDQDL measures
Symptom/ problem list
84.0 (±13.1)
82.2 (±13.8)
0.6232
Effects of kidney disease
90.0 (±11.8)
92.1 (±7.2)
0.4215c
Burden of kidney disease
71.2 (±24.8)
67.4 (±19.1)
0.5460
SF-12 physical score
44.9 (±8.3)
45.2 (±9.2)
0.9331
SF-12 mental score
49.9 (±10.1)
45.4 (±11.7)
0.1243
Table 3.1 Baseline characteristics of the participants by treatment group given by the mean
a

%=column percentage
P-value corresponds to the two sample independent T-test for continuous variables and the χ2 test for categorical variables.
c
an indication of using the Satterthwaite p-value for having the constant variance assumption violated.
d
Use of the Morisky Medication Adherence Scale is protected by United States copyright laws. Permission for use is required. A
license agreement is available from Donald E. Morisky, Department of Community Health Sciences, University of California,
Los Angeles School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772.
b
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Characteristic

Usual Care,
n=32
Median (Q1,Q3)
or n (%a)

Home-Based Renal Care,
n=24
Median (Q1,Q3)
or n (%)

p-valueb

Demographics
Age, yr
49.5 (43.5, 56.0)
48.5 (41.5, 54.5)
0.5397
Women
16 (50%)
16 (66.7%)
0.2785
High school education, %
22 (68.8%)
17 (70.8%)
1.0000
Primary outcome measures
Patient activation total score
60.6 (55.6, 72.6)
57.3 (50.0, 67.9)
0.2603
Patient activation level ≥ 3
25 (78.1%)
17 (70.8%)
0.5507
Secondary outcome measures
Body mass index, kg/m2
31.0 (26.7, 34.4)
33.6 (26.3, 36.5)
0.3892
BP, mm HG
Systolic
122.3 (118.7, 139.7)
130.7 (119.5, 137.7)
0.5291
Diastolic
80.3 (77.0, 86.0)
79.7 (70.3, 92.0)
0.6309
HbA1c, %
8.1 (6.1, 10.2)
9.4 (6.8, 11.3)
0.4265
Glucose, mg/dl
134.5 (118.7, 139.7)
149.5 (106.4, 239.2)
0.4816
Serum total protein, mg/dl
7.5 (7.3 ,7.8)
7.6 (7.2, 8.0)
0.8117
Serum cholesterol, mg/dl
174.0 (144.5, 198.5)
197.0 (172.0, 247.5)
0.0113
Serum triglycerides, mg/dl
169.4 (92.0, 235.5)
162.6 (122.4, 270.7)
0.5131
Serum HDL cholesterol, mg/dl
45.5 (36.5, 57.0)
45.5 (38.0, 55.0)
0.8554
Serum LDL cholesterol, mg/dl
99.0 (86.0, 127.0)
117 (107.5, 140.5)
0.0228
2
eGFR, ml/min per 1.73 m
111.4 (68.3, 168.8)
139.7 (114.9, 179.3)
0.0698
Urine ACR, mg/g
348.8 (75.9, 992.1)
135.5 (80.2, 263.9)
0.1382
hsCRP, mg/L
2.1 (1.3, 5.4)
6.3 (0.7, 11.1)
0.1133
Morisky scorec
3.6 (2.1, 5.8)
4.5 (2.8, 4.8)
0.3779
KDQDL measures
Symptom/ problem list
86.4 (76.1, 92.0)
86.4 (77.3, 93.2)
0.6749
Effects of kidney disease
95.3 (81.3, 100.0)
93.8 (87.5, 96.9)
0.9517
Burden of kidney disease
68.8 (50.0, 100.0)
62.5 (50.0, 87.5)
0.4914
SF-12 physical score
45.2 (40.1, 50.9)
48.6 (40.9, 51.8)
0.6511
SF-12 mental score
52.7 (43.2, 57.9)
48.4 (35.7, 55.1)
0.1069
Table 3.2 Baseline characteristics of the participants by treatment group given by the median
a

%=column percentage
P-value corresponds to the Wilcoxon Rank Sum Test for continuous variables and the χ 2 test for categorical variables.
c
Use of the Morisky Medication Adherence Scale is protected by United States copyright laws. Permission for use is required. A
license agreement is available from Donald E. Morisky, Department of Community Health Sciences, University of California,
Los Angeles School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772.
b
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Generalized Estimating Equations
Generalized Estimating Equations (GEE) were introduced by Liang and Zeger (1985).36 GEE is
not a likelihood-based method. It uses pseudo maximum likelihood (PML) method rather than maximum
likelihood (ML) to estimate the model parameters. The PML method is based on the exponential family.
When estimating parameters using the ML method, one must have the correct specification of the
likelihood function. If misspecified, ML estimation could result in invalid conclusions. On the contrary,
PML method allows for consistent estimation of the mean structure even if the covariance structure is
misspecified. However, the efficiency is lowered when the covariance structure is misspecified.37
GEE arises from normality-based log-likelihood without assuming the response is normally
distributed.38 GEE were appropriate to use for the home-based renal care (HBRC) data analysis because
we collected repeated measurements of variables of interest over time. GEE allows for modelling
potentially correlated data accounting for the household clustering. It was appropriate to model both
categorical and continuous response variables using GEE.
Pseudo Maximum Likelihood (PML) Method
The PML method is a generalization of the ML method such that it allows for a partial model
misspecification of a density from the linear exponential family.27 When using PML estimation, only the
mean structure must be correctly specified.27 In GEE, one can choose the mean structure by using a link
function from the generalized linear model.27 Further, the existence of a variance matrix is assumed but
the correct specification of the covariance matrix is not required.27 Also, we assume that the pseudo
distribution is in the linear exponential family with fixed nuisance parameter.27 A nuisance parameter is
any parameter that is not of direct interest but must be accounted for in the analysis to estimate the
parameters of direct interest. PML is computed by first replacing the nuisance parameters in the model by
estimates which in turn reduces the system of likelihood equations (hence called partial ML) and secondly
solving the reduced system of equations for the parameters of interest (i.e. the non-nuisance parameters).39

19

In essence, GEE does not specify a complete joint distribution—rather, it uses a marginalized joint
distribution in estimating the model parameters.27 It is important to note that if covariance structure is
misspecified, the standard errors will be underestimated.27 When the covariance structure is correctly
specified, the PML solution will agree with the ML estimation.
Covariance Structure
GEE allows for heterogeneity of variance. To specify the covariance structure, firstly we obtained
the Quasi-likelihood under the Independence model Criterion (QIC)40 using the saturated model under
each covariance structure type including exchangeable (EXCH), compound symmetry (CS), unstructured
(UN) and autoregressive (AR) covariance structure patterns. Secondly, we compared the obtained QICs
from all conducted saturated models, covering all covariance structure types, such that a covariance
structure model with the smallest QIC was deemed to be the most adequate.40 In the HBRC study, we
used EXCH covariance structure because it gave the smallest QIC score (Table 3.3). The QIC score is
analogous to AIC score used for fitting likelihood-based methods. Hence, a small QIC indicates a good fit
of the model.

Covariance Pattern Model

QIC

EXCH

52.3621

CS

52.3621

UN

52.3789

AR

52.6008

Table 3.3 Covariance Structure given by the smallest QIC score
Logistic Regression Model
We had four binary outcomes in this study. The primary outcome of interest was PAM level
where 1 indicated “activation” and 0 indicated “lack of activation” of patient-involvement in the
management of their care. The other three secondary binary outcomes were the following KDQDL
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measures, where 1 indicated improvement in quality of health: (i) Symptom/ Problem List, (ii) Effects of
Kidney Disease, and (iii) Burden of Kidney Disease. Multiple logistic regression models were employed
to examine the effect of the primary exposure (i.e. home-based renal care) on the odds of event of interest
in these outcomes while adjusting for (A) outcome levels at baseline only, and (B) outcome levels and
imbalanced covariates at baseline including Cholesterol, LDL, and hsCRP. The functional form for
Model-A and Model-B were presented below and illustrated only for the primary outcome noting that the
same functional form was applied for the secondary outcomes.
Model-A: Adjusting for outcome levels at baseline only:
When modeling PAM level, the outcome response was PAM level at 12 months, the primary
exposure was Treatment group, and the adjusted-for IV was PAM level at baseline. The results from these
logistic models were presented in the bottom of Table 3.6.
Let Z be an indicator of the binary Treatment with 1 for home-based renal care (HBRC) and 0 for
the standard clinical care (SC), X1 be the baseline level of the primary outcome of interest, and Y be the
primary outcome of interest. Then, mathematically, the logistic regression model for estimating the
treatment effect was:
[1] logit (π) = ln (

⇔π=

π
1−π

) = β0 + γZ + β1X1 + ε

exp(β0 + γZ + β1 X1 + ε)

1+ exp(β0 + γZ + β1 X1 + ε)

,

where γ was the estimated parameter for the treatment effect and π = Pr(Y=1).
Model-B: Adjusting for outcome levels and imbalanced covariates at baseline:
When modeling PAM level, the outcome response was PAM level at 12 months, the primary
exposure was Treatment group, and the IVs that were adjusted for were PAM level at baseline,
Cholesterol level (continuous measure), LDL (continuous measure), and hsCRP (continuous measure)—
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the imbalanced baseline covariates. The results from these logistic models were presented in bottom of
Table 3.7.
Let Z be an indicator of the binary Treatment with 1 for home-based renal care (HBRC) and 0 for
the standard clinical care (SC), X1 be the baseline level of the primary outcome of interest, X2 be the
baseline cholesterol level, X3 be the baseline LDL level, X4 be the baseline hsCRP level, and Y be the
primary outcome of interest. Then, mathematically, the logistic regression model for estimating the
treatment effect was:
[2] logit (π) = ln (

⇔π=

π
1−π

) = β0 + γZ + β1X1 + β2X2 + β3X3 + β4X4 + ε

exp(β0 + γZ + β1 X1 + β2 X2 + β3 X3 + β4 X4 + ε)

1+ exp(β0 + γZ + β1 X1 + β2 X2 + β3 X3 + β4 X4 + ε)

,

where γ was the estimated parameter for the treatment effect and π = Pr(Y=1).
Checking Assumptions
For our logistic regression analysis, we used GEE that do not assume that the responses are
independent. Though it was not necessary to check independence, normality and constant variance for
GEE models, we still examined the QQ-plots for normality because GEE is more efficient when
estimating parameters for normally distributed data.
Outliers/Influential Points
We checked the standardized Pearson chi-square residuals to identify outlying points on the Y
direction, leverage to determine outlying points on the X direction outliers, and Cook’s distance to
determine influential points. Standardized Pearson's chi-square residuals in the absolute value that were
larger than 3.84 (i.e. critical value of the Chi-square distribution with one degrees of freedom) were
deemed outliers in the Y direction while leverage values that exceeded
parameters, were deemed outliers in the X direction.
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2p
n

, where p was the number of

For the HBRC data, we defined X outliers to be any observations with leverage greater than
0.0714 for Model-A and 0.1786 for Model-B. We further defined influential points to be any observations
with Cook’s D greater than 1.41 Table 3.4 showed the values of standardized residuals, leverage, and
Cook’s D for the potential outliers or influential points identified for both models when modeling PAM
level. We note that Standardized Pearson's chi-square residuals were calculated with respect to the data
without clustering. Table 3.4 revealed one outlying point in the Y direction for Model-A and 14 outlying
points on the X direction for Model-A and 7 for Model-B. No influential points were found in both
models according to Cook’s D.
PAM level PAM level
Standardized
Cook’s
Group
Leverage
baseline
12 months
residuals
D
1 2441-1
1
0
Intervention
4.640
0.034
0.252
2 1008-1
0
0
Control
0.724
0.118
0.029
3 1008-2
0
0
Control
0.724
0.118
0.029
4 1071-4
0
1
Intervention
-0.484
0.096
0.009
5 1123-3
0
0
Control
0.724
0.113
0.017
6 1341-1
0
1
Control
-1.558
0.111
0.107
7 1581-1
0
0
Control
0.724
0.111
0.022
8 1654-2
0
1
Intervention
-0.484
0.102
0.011
9
179-1
0
1
Intervention
-0.484
0.096
0.009
10 1922-2
0
1
Intervention
-0.484
0.096
0.009
11 2064-2
0
0
Intervention
2.292
0.101
0.209
12 2165-6
0
1
Intervention
-0.484
0.096
0.009
13 332-1
0
1
Intervention
-0.484
0.096
0.009
14 383-5
0
0
Control
0.724
0.111
0.022
15 961-6
0
1
Control
-1.558
0.111
0.090
1 1105-1
1
1
Intervention
-0.644
0.523
0.080
2 1341-1
0
1
Control
-1.499
0.207
0.105
3 1654-2
0
1
Intervention
-0.463
0.512
0.041
4 2064-2
0
0
Intervention
3.137
0.196
0.410
5 2165-6
0
1
Intervention
-0.511
0.194
0.012
6 2441-1
1
0
Intervention
0.516
0.554
0.055
7
961-6
0
1
Control
-1.212
0.233
0.058
Table 3.4: Possible outlying points in the X and Y direction and influential points when modeling PAM
level for Model-A and Model-B.

Model-B

Model-A

ID

23

Figure 3.4 Identifying influential points in Model-A
when modeling PAM level

Figure 3.5 Identifying influential points in Model-B
when modeling PAM level

Transformation: Categorization
Three variables (secondary outcomes) in the kidney disease quality of life survey (KDQOL)
measures displayed ceiling effect where the primary exposure no longer had an effect on them. For ease
of interpretation and to arrive at a more meaningful conclusion, these three continuous variables were
transformed into binary variables. Symptom/Problems List, Effects of Kidney Disease, and Burden of
Kidney Disease were each categorized into binary variables “improvement/lack of improvement”.
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There were not clinically relevant thresholds for determining improvements in each of these
variables. Instead, we first identified optimal thresholds using
QQ-plots as an informal technique by identifying points at which
the curvature changes or inflection points occur. Secondly, we
confirmed these thresholds formally by using the area under the
ROC curve (AUC). This formal technique relies on either
minimizing the Euclidean distance of the ROC curve from the
point (0, 1) or maximizing the Youden Index.42 These two
distances that either minimized D or maximized J were illustrated

Figure 3.6 Using the ROC curve to find
the optimal threshold point

in Figure 3.6.
Using the ROC curve to find the optimal “cut-off” threshold
1. Maximizing the Youden Index
One way to find the optimal cut-off point is to maximize the Youden Index denoted by J. Let Sn
be sensitivity and Sp be specificity, then J = max [Sn + Sp].42 The idea is to find a point where the distance
between the Y = X line and the ROC curve is maximized. In turn, this maximizes the difference between
the true positive rate and the false positive rate.
2. Minimizing the Euclidean distance
Another way to find the optimal cut-off point is to minimize the Euclidean distance denoted by D.
D is the distance between (0, 1) and the ROC curve and is given by D = √(1 − Sn)2 + (1 − Sp)2.42 This
would also maximize the difference between the true positive rate and the false positive rate.
We used the 12 month measurements to generate the ROC curve then calculated both J and D to
determine the optimal cut-off points for the three variables. If they were in disagreement, we used the
minimized D as the optimal cut-off point. For Symptoms/Problems List, Effect of Kidney Disease, and
Burden of Kidney Disease, probability of 0.438 corresponded to a score of 79.545, probability of 0.439
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corresponded to a score of 96.875 and probability of 0.462 corresponded to a score of 87.5 respectively.
This was presented in Table 3.5.

Symptoms/Problems List
Effect of Kidney Disease
Burden of Kidney Disease

Probability at
which J maximized
0.379
0.439
0.462

Probability at which
D is minimized
0.438
0.439
0.462

Optimal
Cut-off
79.545
96.875
87.5

Table 3.5 Corresponding probabilities with corresponding optimal cut-offs at maximized J and at
minimized D.

Figure 3.7 visually illustrates the formal and informal ways of identifying the optimal threshold
for Symptoms/Problems List at 12 months. In particular, the QQ-plot in the top left panel showed an
inflection point around the 25th percentile which was also highlighted in the distribution/histogram of the
variable at the bottom left panel at 80. Formally, this threshold was indeed found to give the minimal
Euclidean distance D between the ROC curve and the (0, 1) point. Note that quantiles of this variable
emphasized the ceiling effect and hence justifying the use of optimal cut-off.
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Figure 3.7 Identifying optimal cut-off for Symptoms/Problems List. Top left panel: QQ-plot of
Symptoms/Problems List at 12 months, Top right panel: ROC curve indicating classification between
improvement and lack of improvement for the Symptoms/Problems List based on optimal cut-off between
Treatment groups; Bottom left panel: The distribution of Symptoms/Problems List at 12 months with a reference
line at the optimal threshold, and Bottom right panel: Quantiles of the Symptoms/Problems List at 12 months.
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Figure 3.8 Identifying optimal cut-off for Effect of Kidney Disease. Top left panel: QQ-plot of Effect of
Kidney Disease at 12 months, Top right panel: ROC curve indicating classification between improvement and
lack of improvement for the Effect of Kidney Disease based on optimal cut-off between Treatment groups;
Bottom left panel: The distribution of Effect of Kidney Disease at 12 months with a reference line at the optimal
threshold, and Bottom right panel: Quantiles of the Effect of Kidney Disease at 12 months.
Figure 3.8 visually illustrates the formal and informal ways of identifying the optimal threshold
for Effect of Kidney Disease at 12 months. Informally, in the QQ-plot in the top left panel showed an
inflection point around the 50th percentile which was also highlighted in the distribution/histogram of the
variable at the bottom left panel at 95. Formally, this threshold was indeed found to give the minimal
Euclidian distance D between the ROC curve and the point (0, 1) and the maximal Youden Index J
between the ROC curve and Y = X line. Note that quantiles of this variable emphasized the ceiling effect
and hence justifying the use of optimal cut-off.
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Figure 3.9 Identifying optimal cut-off for Burden of Kidney Disease. Top left panel: QQ-plot of Burden of
Kidney Disease at 12 months, Top right panel: ROC curve indicating classification between improvement and
lack of improvement for the Burden of Kidney Disease based on optimal cut-off between Treatment groups;
Bottom left panel: The distribution of Burden of Kidney Disease at 12 months with a reference line at the optimal
threshold, and Bottom right panel: Quantiles of the Burden of Kidney Disease at 12 months.

Figure 3.9 visually illustrates the formal and informal ways of identifying the optimal threshold
for Burden of Kidney Disease at 12 months. Informally, in the QQ-plot in the top left panel showed an
inflection point between the 50th and 70th percentile which was also highlighted in the distribution/
histogram of the variable at the bottom left panel at 85. Formally, this threshold was indeed found to give
the minimal Euclidian distance D between the ROC curve and the point (0, 1) and the maximal Youden
Index J between the ROC curve and Y = X line. Note that quantiles of this variable emphasized the
ceiling effect and hence justifying the use of optimal cut-off.
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Linear Regression Model
The primary outcome of interest, PAM score, was a continuous response variable ranging from 0
to 100. There were also 16 other continuous variables (secondary outcomes) of interest including but not
limited to body mass index (BMI) and cholesterol. To obtain the treatment effect, multiple linear
regression models were employed to examine the effect of the primary exposure (i.e. home-based renal
care) on the mean of outcome of interest while adjusting for (A) outcome scores at baseline only, and (B)
outcome scores and imbalanced covariates at baseline including Cholesterol, LDL, and hsCRP. The
functional form for Model-A and Model-B were presented below and illustrated only for the primary
outcome noting that the same functional form was applied for the secondary outcomes.
Model-A: Adjusting for outcome scores at baseline only:
When modeling PAM score, the outcome response was PAM score at 12 months minus the
baseline measurements for PAM, the primary exposure was Treatment group, and IV that was adjustedfor was PAM scores at baseline. The results from these linear models were presented in the top of Table
3.6.
Let Z be an indicator of the binary Treatment with 1 for home-based renal care (HBRC) and 0 for
the standard clinical care (SC), X1 be the baseline measurement of the continuous variable of interest and
Y be the difference between the 12-month measurement and the baseline measurement. Mathematically,
the linear regression model for estimating the treatment effect was:
[3] Y = β0 + γZ + β1X1 + ε ,
where γ is the estimated parameter for the treatment effect.
Model-B: Adjusting for outcome scores and imbalanced covariates at baseline:
When modeling PAM score, the outcome response was PAM score at 12 months minus PAM
score at baseline, the primary exposure was Treatment group, and our adjusted-for IVs were PAM score
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at baseline, Cholesterol level (continuous measure), LDL (continuous measure), and hsCRP (continuous
measure)—the imbalanced baseline covariates. The results from these linear regression models were
presented in top of Table 3.7.
Let Z be an indicator of the binary Treatment with 1 for home-based renal care (HBRC) and 0 for
the standard clinical care (SC), X1 be the baseline scores of the primary outcome of interest, X2 be the
baseline cholesterol level, X3 be the baseline LDL level, X4 be the baseline hsCRP level, and Y be the
primary outcome of interest (i.e. the difference between measurement at 12 month and baseline). Then,
mathematically, the linear regression model for estimating the treatment effect was:
[4] Y = β0 + γZ + β1X1 + β2X2 + β3X3 + β4X4 + ε,
where γ is the estimated parameter for the treatment effect.
Log Transformation
Even though normality and constant variance were not required assumptions due to using GEE,
we still log-transformed variables that were not normally distributed to improve efficiency as GEE is
more efficient with normal data.43 We log-transformed three variables—Triglycerides, Urine ACR and
High sensitivity CRP. We note that the interpretation of the effect switches from change in units in the
outcome to percentage change (i.e. 100%*𝛾̂ ) instead due to the log-transformation of the outcome.44
Estimating Treatment Effect using Linear Regression and Logistic Regression
We constructed Table 3.6 of estimated treatment effect with respect to all of the variables of
interest. For the estimated parameters from the logistic regression model, at α = 0.05, the testing
hypotheses were:
H0: OR = 1 vs. H1: OR ≠ 1.
For estimated patient activation level, we rejected the null hypotheses and concluded that on average, the
odds of patient activation level were 9.7 times higher in the intervention group compared to the control
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group when adjusting for outcome baseline levels (OR=9.7; 95% C.I. 1.7-54.3) and 13.2 times higher in
the intervention group compared to the control group when adjusting for outcome baseline levels and
imbalanced covariates at baseline (OR=13.2; 95% C.I. 1.1-166.1).
For the estimated parameters from the linear regression model, the testing hypotheses, at α = 0.05,
were
H0: γ = 0 vs. H1: γ ≠ 0.
For estimated patient activation total score, we rejected the null hypothesis and concluded that on
average, patient activation score was 16 points higher in the intervention group compared to the control
group when adjusting for outcome baseline scores (𝛾̂=16; 95% C.I. 8.8-23.1; p<0.0001), and 15.7 points
higher in the intervention group compared to the control group when adjusting for outcome baseline
scores and imbalanced covariates at baseline (𝛾̂=15.7; 95% C.I. 7.6-23.8). For estimated body mass index
(BMI), we rejected the null hypothesis and concluded that on average, BMI was 1.2 lower in the
intervention group compared to the control group when adjusting for outcome baseline scores (𝛾̂=-1.2;
95% C.I. -2.2 to -0.2; p=0.0212), and -1.0 points lower in the intervention group compared to the control
group when adjusting for outcome baseline scores and imbalanced covariates at baseline (𝛾̂=-1.0; 95%
C.I. -2.0 to -0.1; p=0.0392). For high sensitivity CRP, we rejected the null hypothesis and concluded that
on average, hsCRP was lower in the intervention group compared to the control group by 70% (𝛾̂=-0.7;
95% C.I. -1.0 to -0.3; p<0.0001), and similarly when adjusting for outcome baseline scores and
imbalanced covariates at baseline (𝛾̂=-0.7; 95% C.I. -1.0 to -0.3; p=0.0001). For all other variables, we
failed to reject the null hypothesis. We note that when running the same models while removing the
influential points we obtained similar results as seen in the right most columns of Tables 3.6 and 3.7.
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With Influential Point

Logistic Regression

Linear Regression

Characteristic
Primary outcome measures
Patient activation total score
Secondary outcome
measures
Body mass index, kg/m2
BP, mm HG
Systolic
Diastolic
HbA1c, %
Glucose, mg/dl
Serum total protein, mg/dl
Serum cholesterol, mg/dl
Serum triglycerides, mg/dla
Serum HDL cholesterol,
mg/dl
Serum LDL cholesterol,
mg/dl
eGFR, ml/min per 1.73 m2
Urine ACR, mg/ga
hsCRP, mg/La
Morisky scoreb
KDQDL measures
SF-12 physical score
SF-12 mental score
Primary outcome measures
Patient activation level ≥ 3
Secondary outcome
measures
KDQDL measures
Symptom/ problem list
Effects of kidney disease
Burden of kidney disease

Treatment Effect
𝛄̂ (95% C.I.)

# of
Without Influential Points
Influential
points
p-value
Treatment Effect p-value
𝛄̂ (95% C.I.)

16 (8.8 to 23.1)

<.0001

1

-1.2 (-2.2 to -0.2)

0.0212

0

-3.7 (-11.2 to 3.7)
-1.9 (-7.4 to 3.6)
-0.8 (-1.9 to 0.4)
-3 (-47.5 to 41.6)
-0.1 (-0.3 to 0.1)
4.8 (-15.9 to 25.5)

0.3237
0.4954
0.1896
0.8957
0.3495
0.6513

5
0
2
0
0
0

-0.1 (-0.3 to 0.2)
-0.1 (-7.9 to 7.7)

0.5573
0.9706

0
0

4.9 (-11.2 to 21)

0.5529

0

9.1 (-12.6 to 30.9)
-0.5 (-1.2 to 0.3)
-0.7 (-1 to -0.3)
-0.2 (-1.1 to 0.8)

0.4110
0.2631
<.0001
0.6903

0
0
0
0

2 (-3.2 to 7.1)
1.2 (-3.3 to 5.8)
OR (95% C.I.)
9.7 (1.7 to 54.3)

0.4531
0.5975
p-value
0.0097

0
5

0.8 (0.2 to 2.9)
2.5 (0.7 to 8.7)
2.7 (0.9 to 8.3)

0.7209
0.1519
0.0862

0
0
0

14.5 (8.1 to 20.9)

<.0001

1.6 (10.3 to 7.1)

0.7120

-1.1 (-2.0 to -0.20)

0.0161

2.3 (-1.9 to 6.4)

0.2841

0

Table 3.6 Estimated treatment effect of intervention compared control for Model-A with and without
influential points
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With Influential Point

Logistic Regression

Linear Regression

Characteristic
Primary outcome
measures
Patient activation total
score
Secondary outcome
measures
Body mass index, kg/m2
BP, mm HG
Systolic
Diastolic
HbA1c, %
Glucose, mg/dl
Serum total protein, mg/dl
Serum cholesterol, mg/dl
Serum triglycerides, mg/dla
Serum HDL cholesterol,
mg/dl
Serum LDL cholesterol,
mg/dl
eGFR, ml/min per 1.73 m2
Urine ACR, mg/ga
hsCRP, mg/La
Morisky scoreb
KDQDL measures
SF-12 physical score
SF-12 mental score
Primary outcome
measures
Patient activation level ≥ 3
Secondary outcome
measures
KDQDL measures
Symptom/ problem list
Effects of kidney disease
Burden of kidney disease

# of
Influential
points

Treatment Effect
𝛄̂ (95% C.I.)

p-value

15.7 (7.6 to 23.8)

0.0001

1

-1.0 (-2.0 to -0.1)

0.0392

0

-4.4 (-11.5 to 2.6)
-4.5 (-10.3 to 1.2)
-0.2 (-1.1 to 0.8)
10.8 (-40.2 to 61.7)
-0.2 (-0.4 to 0)
12 (-10 to 34.1)

0.2182
0.1207
0.7098
0.6790
0.0712
0.2841

5
4
5
0
5
2

0.1 (-0.2 to 0.4)
-2.3 (-10.5 to 6)

0.6466
0.5920

0
0

9.8 (-8.3 to 27.9)

0.2904

1

-0.4 (-27.9 to 27)
0.2 (-0.8 to 1.2)
-0.7 (-1.0 to -0.3)
-0.5 (-1.6 to 0.7)

0.9755
0.6997
0.0001
0.4191

0
1
0
1

2.7 (-3.5 to 8.9)
0.9 (-3.1 to 4.9)
OR (95% C.I.)

0.3950
0.6608
p-value

0
5

13.2 (1.1 to 166.1)

0.0454

0

1.1 (0.3 to 4.1)
3.7 (0.8 to 17.4)
1.8 (0.5 to 6.3)

0.8547
0.0951
0.3749

0
0
0

Without Influential Points

Treatment Effect
𝛄̂ (95% C.I.)

p-value

14.0 (7.5 to 20.5)

<.0001

-2.3 (-12.7 to 8.0)
-0.9 (-6.5 to 4.6)
-0.6 (-1.6 to 0.4)

0.6569
0.7415
0.2374

-0.1 (-0.4 to 0.3)
2.2 (-22.3 to 26.8)

0.6956
0.8590

1.6 (-16.3 to 19.6)

0.8582

0.2 (-0.8 to 1.2)

0.6360

-0.6 (-1.6 to 0.5)

0.2810

1.4 (-2.9 to 5.7)
OR (95% C.I.)

0.5196
p-value

Table 3.7 Estimated treatment effect of intervention compared control for Model-B with and without
influential points
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Cross Validation
To assess if the results of a statistical analysis could be generalizable to an independent dataset,
cross-validation could be used. This technique estimates how accurately a predictive model is performing
in practice. Through cross-validation, one firstly partitions the sample data, repeatedly, into
complementary subsets called the training sets and testing sets respectively. Secondly, one performs the
analysis on the training set, and thirdly validates the analysis on the other subset (called the validation set
or testing set).40
For the purpose of this study, we have conducted cross validation for the models that only
showed statistically significant treatment effect in Table 3.6 (while adjusting for outcome baseline
measurements only) since they didn’t substantially differ than the results from Table 3.7 (while adjusting
for outcome baseline measurements plus imbalanced covariates at baseline).
The matric we use to evaluate cross validation for the linear regression are Root Mean Square
Error (RMSE), the mean absolute error (MAE), and R2 in the test set.45 Here, the RMSE is the standard
deviation of the differences Y-𝑌̂ , while the MAE is the average of their absolute values. For logistic
regression, we used Mean Percentage of Correct Classifications (MPCC) and its corresponding Standard

Logistic
Regression

Linear Regression

Error (SE) as a measure of reliability and validity for the cross validation.46
Treatment Effect
𝛄̂ (95% C.I.)

p-value

16 (8.8 to 23.1)

<.0001

14.2

9.7

0.39

0.0212

2.0

1.5

0.09

hsCRP, mg/La
Primary outcome measures

-1.2 (-2.2 to 0.2)
-0.7 (-1 to -0.3)
OR (95% C.I.)

<.0001
P-value

Patient activation level ≥ 3

9.7 (1.7 to 54.3)

0.0097

Primary outcome measures
Patient activation total score
Secondary outcome
measures
Body mass index, kg/m2

RMSE MAE

Table 3.8 Cross validation results
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R2

0.61 0.47
0.38
MPCC (SE) MPCC (SE)
For training For testing
sets
sets
78.7 (0.08)
77.5 (0.34)

For patient activation score, the R2 reflects that 39% of the variation in patient activation score
can be attributed to the Treatment while adjusting for the baseline measurement of PAM score. For BMI,
9% of the variation in BMI can be attributed to the Treatment while adjusting for the baseline
measurement of BMI. For high sensitivity CRP levels, 38% of the variation in hsCRP levels can be
attributed to the Treatment while adjusting for the baseline measurement of hsCRP. For patient activation
level, MPCC for the testing set reflects that 77.5% of the predictions made using the logistic regression
model for PAM level was correct.
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Chapter 4
Propensity Score
Though the treatment assignment was allotted through randomization, there remained three
variables at baseline that were statistically significantly different between groups—cholesterol, LDL and
hsCRP. This imbalance may have introduced treatment selection bias to the estimated parameters in the
model. As a remedy, we used inverse probability of treatment weighting derived from propensity scores
as a method to reduce the potentially induced bias. Propensity score has been defined as the probability of
being assigned to the intervention group given a set of observed independent variables.47
Let Z be an indicator of the binary Treatment with 1 for home-based renal care and 0 for standard
clinical care—hence primary exposure, xi be a row vector of observed values of imbalanced variables,
and Pr(Z = 1| X = xi) be the propensity towards assignment to Treatment 1 given the observed ith values of
imbalanced variables (i.e. xi).
[5] PSi = Pr(Z = 1| X = xi)
Estimating Propensity Scores
To obtain propensity scores (PSs), we used a multiple logistic regression model including the
three imbalanced variables and the baseline measurement as independent variables (IVs), and Treatment
Z as dependent variable (DV). Note that the primary exposure— Treatment—became the dependent
variable for this intermediate calculation. We note that the choice of only four predictors to calculate PSs
is due to the small sample size especially for the events of interest in the dichotomized primary outcome.
According to Vittinghoff and McCulloch (2006), we need at least 6-7 observation in logistic regression
per event to avoid overfitting and bias in parameters’ estimates. Mathematically, the logistic regression
model for estimating the propensity score was:
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[6] ln (

⇔ PSi =

PSi
1−PSi

) = βxi+ε

exp(𝛃𝐱i +ε)
1 + exp(𝛃𝐱i +ε)

,

where β was a vector of parameters for imbalanced variables and PSi as described in [2].
Properties of Propensity Scores
An important property of propensity score is that if Treatment is independent given the realization
xi, then it is also independent given the propensity score. That is:
[7.1] (y1, y0) ╨ Z | xi
[7.2] ⇒ (y1, y0) ╨ Z | PSi,
where y0 is the response that would have resulted if the participant were assigned to Treatment Z=1 and y1
is the response that would have resulted if the participant were assigned to Treatment Z=0. Equation [7.1]
is referred to as the conditional independence assumption.
Another property of propensity score is that if every participant has a positive probability of
receiving each Treatment given the realization xi, then this is also true given the propensity score. That is:
[8.1] 0 ˂ Pr(Z = 1| X = xi) ˂ 1
[8.2] ⇒ 0 ˂ Pr(Z = 1| PSi) ˂ 1
Equation [8.1] is referred to as the common support assumption. Thus, when these two properties are true,
it is said that Treatment is strongly ignorable given the realization xi.
Inverse Probability of Treatment Weighting (IPTW)
Though the concept of propensity scores was introduced in 1983 by Rosenbaum, it was only in
1987 when he introduced IPTW.48 The idea behind IPTW is that one could minimize treatment selection
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bias by weighting the observations in both groups of the intervention while utilizing the estimated
propensity scores.49 Going from PSs to weights, denoted by W, is done as follows.

[9] Wi =

Zi
PSi

+

(1−Zi )
1−PSi

1
when Z = 1
PSi
⇔ Wi = { 1
when Z = 0
1−PSi

Assumptions for conducting IPTW:
1. Common Support Assumption: This assumption entails having an overlap in the support of the
distribution of PSs between the two groups of the intervention (i.e. between Z=1 and Z=0).

Figure 3.10 Three scenarios for the common support assumption. A: no overlap indication
significant violation of the common support assumption, B: complete overlap indicating
compliance with the common support assumption, and C: partial overlap indicating minor
violation of the common support assumption that could be remedied via some techniques
suggested below.50
A situation as in A of Figure 3.10 suggests that propensity scores is less likely to be helpful in reducing
treatment selection bias; the imbalance is so drastic to the extent that such approach cannot bring any
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benefits. However, in a situation as in C of Figure 3.10 one could resolve the violation of the common
support assumption by either (a) truncate the non-overlapping support segments or (b) utilize the
Stabilized Inverse Probability of Treatment Weighting (SIPTW) as shown below.

2. Balance Assumption:
This assumption entails having similar distribution for the IPTW between the two groups of the
intervention (i.e. between Z = 1 and Z = 0). Figure 3.11 demonstrates a real example showing a graphical
examination for this assumption.

Figure 3.11 An example for the distribution of IPTW from a real example.51
Stabilized Inverse Probability of Treatment Weighting (SIPTW)
Using the unstabilized IPTW has been previously reported to underestimate the variance of the
treatment effect producing narrow confidence intervals that leads to inflation of the probability of a type-I
error.52 The SIPTW can be obtained by multiplying the IPTW by the marginal probability of Treatment to
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Z=1 without considering independent variables. Let θ be the marginal probability of Treatment to 1. The
stabilized SIPTW was calculated as follows:
θ
when z = 1
PSi
[10] SIPTWi = {
1−θ
when z = 0
1−PSi

Application of Propensity Scores: An Example from Nephrology
Applying these principles to the HBRC data. Firstly, the propensity score was estimated
according to equation [6] using PROC LOGISTIC in SAS where we used Treatment as the primary
outcome and cholesterol, LDL, hsCRP, and baseline PAM score as IVs. Secondly, stabilized weights
were created according to equation [10]. Thirdly, weighted simple logistic regression model with PAM
as the primary outcome, using the SIPTW weights, with Treatment as the primary exposure was
employed to produce parameter estimates with minimal treatment selection bias.
1. Testing if SIPTW could balance baseline characteristics between intervention groups:
To assess if the generated weights were able to fix the imbalance at baseline, we have conducted
multiple unweighted logistic regression model in which Treatment (Z) as the primary outcome and
cholesterol, LDL, hsCRP, and baseline PAM score as IVs. The results of this model are presented in
Table 3.1 (and Figure 3.1) and indeed showed the existing imbalance between the two groups with respect
to these IVs via unweighted odds ratio and their corresponding 95% confidence intervals. In particular, a
10 units increase in Cholesterol level was associated with 26.77% (1.024^10=1.2677) higher odds of
being in the intervention group (OR=1.024, 95% C.I. 1.004-1.064; P=0.0102) which is an indication of
imbalance. Furthermore, a one units increase in hsCRP level was associated with 13.8% higher odds of
being in the intervention group (OR=1.138, 95% C.I. 1.038-1.315; P=0.0024) which is another indication
of imbalance.
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To demonstrate that SIPTWs were able to balance baseline characteristics between Treatment
groups, we have employed multiple weighted logistic regression model, using the SIPTWs weights, in
which Treatment (Z) as the primary outcome and cholesterol, LDL, hsCRP, and baseline PAM score as
IVs. The results of this model are presented in Table 3.9 (and Figure 3.12) and indeed showed the
existing imbalance between the two groups with respect to these IVs was diminished. In particular, none
of PAM score at baseline, Cholesterol, LDL, or hsCRP had a significant association with higher odds of
being in the intervention group (p=0.8201, p=0.3195, p=0.7314, and p=0.3098 respectively) which is an
indication of balance.
Estimate

95% Confidence
p-value
Intervals
Pam Score at Baseline
0.964
0.913 to 1.009
0.1163
Cholesterol
1.024
1.004 to 1.064
0.0102
LDL
0.992
0.946 to 1.021
0.6582
hsCRP
1.138
1.038 to 1.315
0.0024
Table 3.9 Unweighted OR Estimates for being in the intervention group with 95% C.I.

Figure 3.12 Unweighted ORs for being in the intervention group with 95% C.I.
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PAM Score at Baseline
Cholesterol
LDL
hsCRP

Estimate
0.995
1.009
0.995
1.041

95% Confidence Intervals
0.952 to 1.039
0.992 to 1.039
0.957 to 1.022
0.964 to 1.149

p-value
0.8201
0.3195
0.7314
0.3098

Table 3.10 Weighted OR Estimates of being in the Treatment group with 95% C.I.

Figure 3.13 Weighted ORs of being in the Treatment group with 95% C.I.
2. Checking Assumptions
Before using the estimated propensity score, we checked model assumptions. First, the
conditional independence assumption was met because the outcome of one participant did not affect that
of another participant. This was assumed by random selection of the sample participants. Then, we
checked the common support or the overlap condition assumption. Each participant must have a non-zero
probability of receiving either of the Treatment options in a randomized controlled trial.
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Figure 3.14 Common Support Assumption
As Figure 3.14 shows, there was a partial overlap in the distribution of PSs for the control and
intervention groups. No overlap would suggest that there are too many pre-existing differences between
groups for causal inference. Because of the partial overlap in the distribution of PSs, we proceeded to
calculate the inverse probability of treatment weight using PSs.
Calculating the Stabilized Inverse Probability of Treatment Weights
To calculate the stabilized inverse probability of treatment weighting, we first calculated the
marginal probability of Treatment Z = 1. Using the HBRC data, we found that θ was 0.4259. In other
words, the probability of being assigned to the home-based renal care group was 42.9%. In turn, the
probability of being assigned to the standard clinical care group was 57.1%. Then, we calculated SWs
using equation [10]. Figure 3.15 showed that the distribution of the SIPTWs between groups were similar,
which is an indication of balance.
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Figure 3.15 Distribution of stabilized inverse probability of treatment weight
Before using the SIPTWs to estimate the parameters again, we checked the odds ratio estimates to
ensure that we have corrected the imbalance of the treatment assignment. Table 3.10 showed the
estimated odds ratio and the corresponding 95% confidence intervals. The testing hypotheses were H0:
odds ratio = 1 vs. H1: odds ratio ≠ 1 at 95% confidence. Each of the 95% confidence intervals for the
baseline PAM score, cholesterol, LDL and hsCRP included 1. We failed to reject the null hypotheses and
concluded that the treatment assignment was independent from the outcomes of interest.
Applying the SIPTWs to reduce treatment selection bias
Using SIPTWs, we estimated the parameters of the original regression models again to correct the
treatment selection bias. Table 3.11 showed a side-by-side comparison of estimated parameters given by
regression models with and without the SIPTWs.
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Without SIPTW

Logistic Regression

Linear Regression

Characteristic
Primary outcome
measures
Patient activation total score
Secondary outcome
measures
Body mass index, kg/m2
BP, mm HG
Systolic
Diastolic
HbA1c, %
Glucose, mg/dl
Serum total protein, mg/dl
Serum cholesterol, mg/dl
Serum triglycerides, mg/dla
Serum HDL cholesterol,
mg/dl
Serum LDL cholesterol,
mg/dl
eGFR, ml/min per 1.73 m2
Urine ACR, mg/ga
hsCRP, mg/La
Morisky scoreb
KDQDL measures
SF-12 physical score
SF-12 mental score
Primary outcome
measures
Patient activation level ≥ 3
Secondary outcome
measures
KDQDL measures
Symptom/ problem list
Effects of kidney disease
Burden of kidney disease

With SIPTW

Treatment Effect
𝛄̂ (95% C.I.)

p-value

Treatment Effect
𝛄̂ (95% C.I.)

p-value

16 (8.8 to 23.1)

<.0001

15.6 (8.3 to 22.9)

<.0001

-1.2 (-2.2 to -0.2)

0.0212

-0.7 (-1.7 to 0.3)

0.1446

-3.7 (-11.2 to 3.7)
-1.9 (-7.4 to 3.6)
-0.8 (-1.9 to 0.4)
-3 (-47.5 to 41.6)
-0.1 (-0.3 to 0.1)
4.8 (-15.9 to 25.5)
-0.1 (-0.3 to 0.2)
-0.1 (-7.9 to 7.7)

0.3237
0.4954
0.1896
0.8957
0.3495
0.6513
0.5573
0.9706

-2.5 (-9.7 to 4.7)
-1.1 (-6.2 to 3.9)
-0.2 (-1.2 to 0.9)
-0.1 (-0.4 to 0.1)
4.6 (-16 to 25.1)
0.04 (-0.2 to 0.3)
-1.7 (-9.7 to 6.3)

0.4980
0.6635
0.7425
0.6177
0.2398
0.6633
0.7785
0.6782

4.9 (-11.2 to 21)

0.5529

3.1 (-12.1 to 18.4)

0.6886

9.1 (-12.6 to 30.9)
-0.5 (-1.2 to 0.3)
-0.7 (-1 to -0.3)
-0.2 (-1.1 to 0.8)

0.4110
0.2631
<.0001
0.6903

7.8 (-13.4 to 29.0)
-0.08 (-1.0 to 0.8)
-0.6 (-0.9 to -0.3)
-0.6 (-1.6 to 0.3)

0.4724
0.8600
0.0001
0.2107

2 (-3.2 to 7.1)
1.2 (-3.3 to 5.8)
OR (95% C.I.)

0.4531
0.5975
P-value

1.9 (-3.3 to 7.0)
2.6 (-1.1 to 6.2)
OR (95% C.I.)

0.4765
0.1635
P-value

9.7 (1.7 to 54.3)

0.0097

8.4 (1.9 to 37)

0.0049

0.8 (0.2 to 2.9)
2.5 (0.7 to 8.7)
2.7 (0.9 to 8.3)

0.7209
0.1519
0.0862

0.9 (0.2 to 3.2)
3.0 (0.9 to 10.3)
2.7 (0.8 to 8.9)

0.8572
0.0810
0.1105

11.7 (-34.2 to 57.6)

Table 3.11 Estimated treatment effect of intervention compared control with and without SW
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Chapter 5
Discussion
In conclusion, after using SIPTW to adjust for the imbalanced variable at baseline, the estimated
average change in the difference in PAM scores is 15.6 points higher in the treatment group compared to
the control group while holding the baseline PAM scores constant. When PAM score is categorized into
PAM level, we observe that participants in the treatment group are 8.4 times more likely to be activated at
12 months compared to the control group while holding the baseline PAM scores constant. SIPTWs could
be used to reduce treatment selection bias by 2.5% for the continuous outcome variable and 13.4% for the
binary outcome variable. The impact of SIPTWs in reducing treatment selection bias could be more
pronounced in observational studies. The selection of participants with diabetes mellitus in the beginning
of the study may have contributed to the observed bias in the parameter estimation.
As previously mentioned, the HBRC data were collected through a randomized controlled trial.
Because of the randomization, the implementation of propensity score may not have been substantially
impactful given that among 21 baseline covariates 18 of them were balanced to start with. The subject
matter expert was interested in analyzing the data only for the diabetic subgroup from the collected data.
We did not perform another round of randomization for the selection of this subset participants with
diabetes. Though it was likely that a subset selected from the randomized groups was still random, it was
not guaranteed. This was supported by the three variables that showed statistically significant difference
at baseline.
Additionally, there were 56 total participants of which 24 participants were in the intervention
group. This was a small sample size for implementation of propensity score. There might be insufficient
data to reach meaningful results. The small sample size also limited the number of covariates used to
generate the propensity scores. Vittinghoff and McCulloch (2007) found that it is acceptable to relax the
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rule of thumb of 10 or more Event Per Variable (EPV) to 5-9 EPV in using a logistic regression model.53
They defined the acceptable threshold as confidence interval coverage of greater than 93 percent, type 1
error rate of lower than 7 percent or relative bias less than 15 percent. By this finding, we were limited to
having a parsimonious model with 2 to 4 covariates in the logistic regression model that was used to
generate the propensity scores. To avoid overfitting, we only adjusted for 4 covariates to stay within this
acceptable range of EPVs.
Another limitation brought on by the small sample size in regard to the propensity score is that it
was not appropriate to trim the dataset. The restriction of treatment comparisons to subjects with a
common range of covariates can improve the validity of estimated treatment effects.54 With large sample
size, propensity score trimming can increase the validity of the treatment effect estimates.55 However, any
analysis done using the trimming method will not be causal in the sense that they do not apply to any
clearly defined population because of the range restriction.55 Again, this technique did not apply well to
this data because of its small sample size.
Thirdly, another limitation of the analysis of this study is the potentially inflated Treatment
estimates. This is because we estimated the Treatment effect on the difference between baseline to 12
months measures while adjusting for the baseline measurements. Glymour (2005) reported that even
though the baseline adjustments improve efficiency and eliminates confounding, adjusting for baseline
measures could introduce bias to the estimated parameters in situations where the primary exposure
predicts baseline level of the outcome.56 In particular, it gives two common situations where this could
occur—(1) when the measurement reliability is imperfect or the latent variable is instable and (2) when
the change has already occurred prior to the baseline measurement, the rate of change experienced in the
past predicts that of the future, and exposure is unaffected by baseline function. When either of these
situation holds true, the baseline adjusted model induces a spurious correlation between the exposure and
the change score because the exposure is likely to be a predictor on the outcome even under the null
assumption of no causal effect.
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Finally, in using the ROC analysis to arrive at the optimal cut-off point, we opted to use the
Euclidean distance D rather than the Youden Index J in situations where the two values were not in
agreement. While both methods are very practical in dichotomizing a continuous variable, there are
advantages to using the Youden Index J over the Euclidean distance D. According to Perkins and
Schisterman (2005), the Youden Index J is more robust against measurement error compared to the
Euclidean distance D given by an approximate confidence interval generated using the delta method.57
This may be of concern in our study because the data collection was not done by a laboratory machine.
Also, J has easier clinical interpretation because it does not involve a quadratic term in its calculation.
However, another study by Unal (2017) shows that the Euclidean distance D consistently reduced the
relative bias and MSE compared to the Youden Index J.35 For this reason, we used the Euclidean distance
D. It would be interesting to compare the treatment estimates given by the two different methods.
For a future study, it would be beneficial to conduct the randomized controlled trial on the
diabetic patients rather than the CKD patients with diabetes to have a better interpretation of the treatment
effect on the participants. It would provide better insight into the direct effect that the home-based renal
care has on diabetic patients rather than the effect that it has on CKD patients with diabetes. Also, a
concern that a local Zuni chief had was that people with compromised health did not get the treatment.
This community would benefit from conducting a delayed randomized trial rather than the traditional
randomized controlled trial because all participants in the study would be able to get an intervention at
some point in the trial.
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